Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction

In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD pati...

Full description

Saved in:
Bibliographic Details
Published inmSystems Vol. 3; no. 1
Main Authors Zhou, Youlian, Xu, Zhenjiang Zech, He, Yan, Yang, Yunsheng, Liu, Le, Lin, Qianyun, Nie, Yuqiang, Li, Mingsong, Zhi, Fachao, Liu, Side, Amir, Amnon, González, Antonio, Tripathi, Anupriya, Chen, Minhu, Wu, Gary D., Knight, Rob, Zhou, Hongwei, Chen, Ye
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.01.2018
Subjects
Biomarkers
Crohn's disease
Diagnosis
Disease
disease activity
Dysbacteriosis
Fecal microflora
Feces
Firmicutes
Gastroenterology
Geography
gut microbiota
Health care
Hospitals
Host-Microbe Biology
Immunotherapy
Inflammatory bowel disease
Inflammatory bowel diseases
Infliximab
infliximab treatment
Intestinal microflora
Intestine
Laboratories
Microbiomes
Microbiota
Minority & ethnic groups
Monoclonal antibodies
Multiculturalism & pluralism
Noninvasive evaluation
Pathogenesis
Research Article
Studies
TNF inhibitors
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Ulcerative colitis
Beijing China
La Jolla California
California
United States > US
China
disease activity
infliximab treatment
gut microbiota
inflammatory bowel disease
Online AccessGet full text

Cover

Abstract In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes. Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn’s disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria ( Enterobacteriaceae ) and a relative decrease in the levels of Firmicutes ( Clostridiales ) were strongly correlated with IBD severity ( P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales , predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn’s disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.
AbstractList Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn's disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria (Enterobacteriaceae) and a relative decrease in the levels of Firmicutes (Clostridiales) were strongly correlated with IBD severity (P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn's disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn's disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria (Enterobacteriaceae) and a relative decrease in the levels of Firmicutes (Clostridiales) were strongly correlated with IBD severity (P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn's disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.
In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes. Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn’s disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria ( Enterobacteriaceae ) and a relative decrease in the levels of Firmicutes ( Clostridiales ) were strongly correlated with IBD severity ( P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales , predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn’s disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.
ABSTRACT Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn’s disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria (Enterobacteriaceae) and a relative decrease in the levels of Firmicutes (Clostridiales) were strongly correlated with IBD severity (P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn’s disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.
Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn’s disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria (Enterobacteriaceae) and a relative decrease in the levels of Firmicutes (Clostridiales) were strongly correlated with IBD severity (P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn’s disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.
Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn's disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of and ( ) and a relative decrease in the levels of ( ) were strongly correlated with IBD severity ( < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly , predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn's disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.
ABSTRACTGut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn’s disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria (Enterobacteriaceae) and a relative decrease in the levels of Firmicutes (Clostridiales) were strongly correlated with IBD severity (P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn’s disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD.IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.
Author He, Yan
Nie, Yuqiang
Liu, Side
Wu, Gary D.
Knight, Rob
Li, Mingsong
Yang, Yunsheng
Liu, Le
González, Antonio
Tripathi, Anupriya
Chen, Minhu
Zhou, Hongwei
Zhou, Youlian
Lin, Qianyun
Amir, Amnon
Chen, Ye
Xu, Zhenjiang Zech
Zhi, Fachao
Author_xml – sequence: 1
  givenname: Youlian
  surname: Zhou
  fullname: Zhou, Youlian
  organization: Department of Gastroenterology, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Gastroenterology, Guangzhou Digestive Disease Center, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China
– sequence: 2
  givenname: Zhenjiang Zech
  surname: Xu
  fullname: Xu, Zhenjiang Zech
  organization: Department of Pediatrics, University of California, San Diego, La Jolla, California, USA, School of Food and Technology, Nanchang University, Nanchang, China, State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang, China
– sequence: 3
  givenname: Yan
  surname: He
  fullname: He, Yan
  organization: Department of Environmental Health, School of Public Health and Tropical Medicine, State Key Laboratory of Organ Failure Research, Southern Medical University, Guangzhou, China, State Key Laboratory of Organ Failure Research, Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China
– sequence: 4
  givenname: Yunsheng
  surname: Yang
  fullname: Yang, Yunsheng
  organization: Institute of Digestive Diseases, Chinese PLA General Hospital, Beijing, China
– sequence: 5
  givenname: Le
  surname: Liu
  fullname: Liu, Le
  organization: Department of Gastroenterology, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China
– sequence: 6
  givenname: Qianyun
  surname: Lin
  fullname: Lin, Qianyun
  organization: Department of Gastroenterology, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China
– sequence: 7
  givenname: Yuqiang
  surname: Nie
  fullname: Nie, Yuqiang
  organization: Department of Gastroenterology, Guangzhou Digestive Disease Center, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China
– sequence: 8
  givenname: Mingsong
  surname: Li
  fullname: Li, Mingsong
  organization: Department of Gastroenterology, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China
– sequence: 9
  givenname: Fachao
  surname: Zhi
  fullname: Zhi, Fachao
  organization: Department of Gastroenterology, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China
– sequence: 10
  givenname: Side
  surname: Liu
  fullname: Liu, Side
  organization: Department of Gastroenterology, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China
– sequence: 11
  givenname: Amnon
  surname: Amir
  fullname: Amir, Amnon
  organization: Department of Pediatrics, University of California, San Diego, La Jolla, California, USA
– sequence: 12
  givenname: Antonio
  surname: González
  fullname: González, Antonio
  organization: Department of Pediatrics, University of California, San Diego, La Jolla, California, USA
– sequence: 13
  givenname: Anupriya
  surname: Tripathi
  fullname: Tripathi, Anupriya
  organization: Department of Pediatrics, University of California, San Diego, La Jolla, California, USA
– sequence: 14
  givenname: Minhu
  surname: Chen
  fullname: Chen, Minhu
  organization: Department of Gastroenterology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
– sequence: 15
  givenname: Gary D.
  surname: Wu
  fullname: Wu, Gary D.
  organization: Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
– sequence: 16
  givenname: Rob
  surname: Knight
  fullname: Knight, Rob
  organization: Department of Pediatrics, University of California, San Diego, La Jolla, California, USA, Department of Computer Science and Engineering, University of California, San Diego, La Jolla, California, USA, Center for Microbiome Innovation, University of California, San Diego, La Jolla, California, USA
– sequence: 17
  givenname: Hongwei
  surname: Zhou
  fullname: Zhou, Hongwei
  organization: State Key Laboratory of Organ Failure Research, Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China
– sequence: 18
  givenname: Ye
  surname: Chen
  fullname: Chen, Ye
  organization: Department of Gastroenterology, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29404425$$D View this record in MEDLINE/PubMed
BookMark eNp9ksFuEzEQQFeoiJbSD-CCVuLCJcHj9cbrCxItpUQqKkL0bHm949Rh125tp5Af4LvxJg20leA0lv3macYzz4s95x0WxUsgUwDavB3iOiYc4pQQaJoJ8CfFAa24mNSE87175_3iKMYlydis4kDFs2KfCkYYo_VB8etslcrPVgffWp9UeWEMhlheOnubo-rLY-sHFb6PlypTMZan6cpZbdO6tK6cO9OrYVDJh3V57H9gX36wEVXEHNXC-Whzous2oP1pB9WWXzFee5eJLwE7q5P17kXx1Kg-4tFdPCwuP55-O_k0Ob84m5-8P5-oWjRpgqAFdB0a01Js-YwJVNCYmeZVxU0noAYUBqghHEAYwylXXVtVSJjmrKurw2K-9XZeLeV1yPWEtfTKys2FDwupQrK6Rzlj9fiFaBhyJrgQpGI11lqrXEEHkF3vtq7rVTtgp9GloPoH0ocvzl7Jhb-VNRek4TQL3twJgr9ZYUxysFFj3yuHfhUlCFEDmzWCZ_T1I3TpV8Hlr5KUEEFFA2zsbrqlVBzoXwKIHDdG7jZGbjZGwqh9db-FP7Xv9iMDfAtsRh_QyDx4NU4sd2T7_6rhUeZO_u-c368F5uw
CitedBy_id crossref_primary_10_1136_egastro_2023_100006
crossref_primary_10_5217_ir_2023_00080
crossref_primary_10_1016_j_ijbiomac_2024_133855
crossref_primary_10_3390_microorganisms12091828
crossref_primary_10_5217_ir_2023_00085
crossref_primary_10_1016_j_isci_2024_111442
crossref_primary_10_1093_ecco_jcc_jjae084
crossref_primary_10_1142_S0192415X24500514
crossref_primary_10_1016_j_csbj_2022_12_053
crossref_primary_10_1177_17562848241258360
crossref_primary_10_62347_XILL3707
crossref_primary_10_3390_biomedicines13030708
crossref_primary_10_1021_acs_jafc_4c03544
crossref_primary_10_1002_advs_202413128
crossref_primary_10_4103_sjg_sjg_66_24
crossref_primary_10_1080_19490976_2024_2393272
crossref_primary_10_1097_MOG_0000000000000847
crossref_primary_10_1007_s10787_024_01630_9
crossref_primary_10_1177_17562848231173331
crossref_primary_10_58931_cibdt_2024_2334
crossref_primary_10_1016_j_jmii_2024_09_006
crossref_primary_10_3389_fimmu_2021_700570
crossref_primary_10_1002_advs_202410417
crossref_primary_10_5041_RMMJ_10364
crossref_primary_10_1016_j_biopha_2024_117302
crossref_primary_10_1007_s00108_022_01396_8
crossref_primary_10_1016_j_jmb_2024_168841
crossref_primary_10_1097_QCO_0000000000000958
crossref_primary_10_1021_acs_jafc_3c00283
crossref_primary_10_1080_19490976_2021_1943288
crossref_primary_10_1136_bmjopen_2024_094280
crossref_primary_10_1016_j_ygeno_2021_04_011
crossref_primary_10_1016_j_csbj_2024_04_025
crossref_primary_10_5217_ir_2023_00087
crossref_primary_10_1016_j_bpg_2024_101953
crossref_primary_10_1080_19490976_2025_2476570
crossref_primary_10_1002_ueg2_12720
crossref_primary_10_1136_gutjnl_2021_325185
Cites_doi 10.1038/nature11582
10.1126/science.aaf3229
10.1002/ibd.21339
10.1159/000201441
10.1007/s00535-010-0368-4
10.1038/ng.3359
10.1097/01.MIB.0000435759.05577.12
10.3748/wjg.v18.i36.5058
10.1016/j.chom.2014.02.005
10.4103/0971-5916.162091
10.1053/j.gastro.2010.11.058
10.1038/embor.2013.27
10.1111/1751-2980.12161
10.1038/540S100a
10.1136/gutjnl-2014-307410
10.1007/s00535-012-0605-0
10.1126/science.1198469
10.1073/pnas.0804812105
10.1007/s10198-017-0896-4
10.1038/nmeth.f.303
10.1186/gb-2011-12-6-r60
10.1016/j.diagmicrobio.2012.11.022
10.1038/ajg.2010.392
10.1097/MIB.0000000000000036
10.1136/gut.2005.073817
10.1136/gut.2004.043406
10.1097/MPG.0b013e318262a718
10.1056/NEJMoa050516
10.3109/00365528909091339
10.1038/35079107
10.1126/science.aad9948
10.1016/j.febslet.2014.09.039
10.1016/S0140-6736(02)08512-4
10.1097/MEG.0000000000000447
10.1136/gut.2003.025403
10.1016/j.crohns.2009.12.003
10.1186/gb-2012-13-9-r79
10.1038/ismej.2011.139
10.1038/ismej.2012.158
10.1016/j.mimet.2013.07.015
10.1038/nbt.2676
10.1038/35079114
10.1053/j.gastro.2005.12.019
10.1136/gut.2005.082909
10.1038/ajg.2015.149
10.1079/BJN19900088
10.1038/nrgastro.2014.45
10.1053/j.gastro.2011.01.055
10.1053/j.gastro.2013.04.007
10.1038/nrgastro.2012.152
10.1002/ibd.22861
10.1038/nature11053
10.1371/journal.pone.0039242
10.1097/MD.0000000000000051
10.1016/j.patrec.2005.10.010
10.1128/AEM.71.12.8228-8235.2005
10.18637/jss.v028.i05
10.1016/0016-5085(95)90277-5
ContentType Journal Article
Copyright Copyright © 2018 Zhou et al.
Copyright © 2018 Zhou et al. This work is licensed under the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/3.0/ ) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright © 2018 Zhou et al. 2018 Zhou et al.
Copyright_xml – notice: Copyright © 2018 Zhou et al.
– notice: Copyright © 2018 Zhou et al. This work is licensed under the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/3.0/ ) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright © 2018 Zhou et al. 2018 Zhou et al.
DBID AAYXX
CITATION
NPM
3V.
7X7
7XB
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1128/msystems.00188-17
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
Proquest Central
Natural Science Collection
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef



PubMed
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
Geography
DocumentTitleAlternate Gut Microbiota Predicts IBD Diagnosis and IFX Response, Zhou et al
Gut Microbiota Predicts IBD Diagnosis and IFX Response
EISSN 2379-5077
Editor Ercolini, Danilo
Editor_xml – sequence: 1
  givenname: Danilo
  surname: Ercolini
  fullname: Ercolini, Danilo
ExternalDocumentID oai_doaj_org_article_6452379ef4e7497990345e5cca1ddd11
PMC5790872
mSystems00188-17
29404425
10_1128_msystems_00188_17
Genre Journal Article
GeographicLocations Beijing China
La Jolla California
California
United States--US
China
GeographicLocations_xml – name: China
– name: La Jolla California
– name: California
– name: Beijing China
– name: United States--US
GrantInformation_xml – fundername: the Crohn's and colitis foundation of America
– fundername: the National Natural Science Foundation
  grantid: 31322003
– fundername: the National Natural Science Foundation
  grantid: 81570480
– fundername: the National Natural Science Foundation
  grantid: 81700487
– fundername: ;
– fundername: ;
  grantid: 81570480
– fundername: ;
  grantid: 81700487
– fundername: ;
  grantid: 31322003
GroupedDBID 0R~
53G
5VS
7X7
8FE
8FH
8FI
8FJ
AAFWJ
AAGFI
AAUOK
AAYXX
ABUWG
ACPRK
ADBBV
ADRAZ
AFKRA
AFPKN
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CITATION
EBS
EJD
FRP
FYUFA
GROUPED_DOAJ
H13
HCIFZ
HMCUK
HYE
KQ8
LK8
M48
M7P
M~E
O9-
OK1
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RHI
RPM
RSF
UKHRP
NPM
PQGLB
3V.
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-a598t-e1c91ddeffb2eb7649ea18f6c7337fd9151e9f12f07119ff727adb33e04c74d53
IEDL.DBID 7X7
ISSN 2379-5077
IngestDate Wed Aug 27 00:21:14 EDT 2025
Thu Aug 21 18:42:56 EDT 2025
Fri Jul 11 08:11:29 EDT 2025
Fri Jul 25 12:10:46 EDT 2025
Sun Aug 11 18:20:27 EDT 2024
Mon Jul 21 05:49:50 EDT 2025
Tue Jul 01 02:58:50 EDT 2025
Thu Apr 24 23:02:55 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords disease activity
infliximab treatment
gut microbiota
inflammatory bowel disease
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a598t-e1c91ddeffb2eb7649ea18f6c7337fd9151e9f12f07119ff727adb33e04c74d53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Y.Z., Z.Z.X., and Y.H. contributed equally to this article.
Citation Zhou Y, Xu ZZ, He Y, Yang Y, Liu L, Lin Q, Nie Y, Li M, Zhi F, Liu S, Amir A, González A, Tripathi A, Chen M, Wu GD, Knight R, Zhou H, Chen Y. 2018. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems 3:e00188-17. https://doi.org/10.1128/mSystems.00188-17.
OpenAccessLink https://www.proquest.com/docview/2009298145?pq-origsite=%requestingapplication%
PMID 29404425
PQID 2009298145
PQPubID 2045591
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_6452379ef4e7497990345e5cca1ddd11
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5790872
proquest_miscellaneous_1995146897
proquest_journals_2009298145
asm2_journals_10_1128_msystems_00188_17
pubmed_primary_29404425
crossref_citationtrail_10_1128_msystems_00188_17
crossref_primary_10_1128_msystems_00188_17
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-01-01
PublicationDateYYYYMMDD 2018-01-01
PublicationDate_xml – month: 01
  year: 2018
  text: 2018-01-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
– name: Washington
PublicationTitle mSystems
PublicationTitleAbbrev mSystems
PublicationTitleAlternate mSystems
PublicationYear 2018
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_26_2
e_1_3_2_49_2
e_1_3_2_28_2
e_1_3_2_41_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_9_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_54_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_52_2
e_1_3_2_5_2
Liaw A (e_1_3_2_60_2) 2002; 2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_58_2
e_1_3_2_3_2
e_1_3_2_14_2
e_1_3_2_35_2
e_1_3_2_56_2
e_1_3_2_50_2
e_1_3_2_27_2
e_1_3_2_48_2
e_1_3_2_29_2
e_1_3_2_40_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_25_2
e_1_3_2_46_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_17_2
e_1_3_2_59_2
e_1_3_2_6_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_53_2
e_1_3_2_32_2
e_1_3_2_51_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_57_2
e_1_3_2_4_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_55_2
e_1_3_2_2_2
Zhou, Y, He, H, Wang, P, Zhang, T, Lin, M, Wang, H, Nie, Y, Chen, Y (B20) 2015; 27
Ng, SC, Tang, W, Leong, RW, Chen, M, Ko, Y, Studd, C, Niewiadomski, O, Bell, S, Kamm, MA, de Silva, HJ, Kasturiratne, A, Senanayake, YU, Ooi, CJ, Ling, KL, Ong, D, Goh, KL, Hilmi, I, Ouyang, Q, Wang, YF, Hu, P, Zhu, Z, Zeng, Z, Wu, K, Wang, X, Xia, B, Li, J, Pisespongsa, P, Manatsathit, S, Aniwan, S, Simadibrata, M, Abdullah, M, Tsang, SW, Wong, TC, Hui, AJ, Chow, CM, Yu, HH, Li, MF, Ng, KK, Ching, J, Wu, JC, Chan, FK, Sung, JJ (B1) 2015; 64
Prideaux, L, Kang, S, Wagner, J, Buckley, M, Mahar, JE, De Cruz, P, Wen, Z, Chen, L, Xia, B, van Langenberg, DR, Lockett, T, Ng, SC, Sung, JJ, Desmond, P, McSweeney, C, Morrison, M, Kirkwood, CD, Kamm, MA (B35) 2013; 19
Langille, MG, Zaneveld, J, Caporaso, JG, McDonald, D, Knights, D, Reyes, JA, Clemente, JC, Burkepile, DE, Vega Thurber, RL, Knight, R, Beiko, RG, Huttenhower, C (B55) 2013; 31
Ray, K (B8) 2014; 11
Kabeerdoss, J, Jayakanthan, P, Pugazhendhi, S, Ramakrishna, BS (B14) 2015; 142
Liaw, A, Wiener, M (B59) 2002; 2
Yatsunenko, T, Rey, FE, Manary, MJ, Trehan, I, Dominguez-Bello, MG, Contreras, M, Magris, M, Hidalgo, G, Baldassano, RN, Anokhin, AP, Heath, AC, Warner, B, Reeder, J, Kuczynski, J, Caporaso, JG, Lozupone, CA, Lauber, C, Clemente, JC, Knights, D, Knight, R, Gordon, JI (B17) 2012; 486
Kuhn, M (B57) 2008; 28
Cosnes, J, Gower-Rousseau, C, Seksik, P, Cortot, A (B18) 2011; 140
Kolho, KL, Korpela, K, Jaakkola, T, Pichai, MV, Zoetendal, EG, Salonen, A, de Vos, WM (B29) 2015; 110
Atarashi, K, Tanoue, T, Shima, T, Imaoka, A, Kuwahara, T, Momose, Y, Cheng, G, Yamasaki, S, Saito, T, Ohba, Y, Taniguchi, T, Takeda, K, Hori, S, Ivanov, II, Umesaki, Y, Itoh, K, Honda, K (B44) 2011; 331
Rajca, S, Grondin, V, Louis, E, Vernier-Massouille, G, Grimaud, JC, Bouhnik, Y, Laharie, D, Dupas, JL, Pillant, H, Picon, L, Veyrac, M, Flamant, M, Savoye, G, Jian, R, Devos, M, Paintaud, G, Piver, E, Allez, M, Mary, JY, Sokol, H, Colombel, JF, Seksik, P (B28) 2014; 20
Sha, S, Xu, B, Wang, X, Zhang, Y, Wang, H, Kong, X, Zhu, H, Wu, K (B31) 2013; 75
Mao, R, Xiao, YL, Gao, X, Chen, BL, He, Y, Yang, L, Hu, PJ, Chen, MH (B26) 2012; 18
Røseth, AG, Aadland, E, Jahnsen, J, Raknerud, N (B25) 1997; 58
Caporaso, JG, Kuczynski, J, Stombaugh, J, Bittinger, K, Bushman, FD, Costello, EK, Fierer, N, Peña, AG, Goodrich, JK, Gordon, JI, Huttley, GA, Kelley, ST, Knights, D, Koenig, JE, Ley, RE, Lozupone, CA, McDonald, D, Muegge, BD, Pirrung, M, Reeder, J, Sevinsky, JR, Turnbaugh, PJ, Walters, WA, Widmann, J, Yatsunenko, T, Zaneveld, J, Knight, R (B53) 2010; 7
Segata, N, Izard, J, Waldron, L, Gevers, D, Miropolsky, L, Garrett, WS, Huttenhower, C (B56) 2011; 12
Hanauer, SB, Feagan, BG, Lichtenstein, GR, Mayer, LF, Schreiber, S, Colombel, JF, Rachmilewitz, D, Wolf, DC, Olson, A, Bao, W, Rutgeerts, P (B40) 2002; 359
Hugot, JP, Chamaillard, M, Zouali, H, Lesage, S, Cézard, JP, Belaiche, J, Almer, S, Tysk, C, O’Morain, CA, Gassull, M, Binder, V, Finkel, Y, Cortot, A, Modigliani, R, Laurent-Puig, P, Gower-Rousseau, C, Macry, J, Colombel, JF, Sahbatou, M, Thomas, G (B4) 2001; 411
Gevers, D, Kugathasan, S, Denson, LA, Vázquez-Baeza, Y, Van Treuren, W, Ren, B, Schwager, E, Knights, D, Song, SJ, Yassour, M, Morgan, XC, Kostic, AD, Luo, C, González, A, McDonald, D, Haberman, Y, Walters, T, Baker, S, Rosh, J, Stephens, M, Heyman, M, Markowitz, J, Baldassano, R, Griffiths, A, Sylvester, F, Mack, D, Kim, S, Crandall, W, Hyams, J, Huttenhower, C, Knight, R, Xavier, RJ (B9) 2014; 15
McDonald, D, Price, MN, Goodrich, J, Nawrocki, EP, DeSantis, TZ, Probst, A, Andersen, GL, Knight, R, Hugenholtz, P (B54) 2012; 6
Lewis, JD (B24) 2011; 140
Ramanan, D, Bowcutt, R, Lee, SC, Tang, MS, Kurtz, ZD, Ding, Y, Honda, K, Gause, WC, Blaser, MJ, Bonneau, RA, Lim, YA, Loke, P, Cadwell, K (B42) 2016; 352
D’Haens, GR, Panaccione, R, Higgins, PD, Vermeire, S, Gassull, M, Chowers, Y, Hanauer, SB, Herfarth, H, Hommes, DW, Kamm, M, Lofberg, R, Quary, A, Sands, B, Sood, A, Watermeyer, G, Lashner, B, Lemann, M, Plevy, S, Reinisch, W, Schreiber, S, Siegel, C, Targan, S, Watanabe, M, Feagan, B, Sandborn, WJ, Colombel, JF, Travis, S (B27) 2011; 106
Manichanh, C, Rigottier-Gois, L, Bonnaud, E, Gloux, K, Pelletier, E, Frangeul, L, Nalin, R, Jarrin, C, Chardon, P, Marteau, P, Roca, J, Dore, J (B6) 2006; 55
Van den Abbeele, P, Belzer, C, Goossens, M, Kleerebezem, M, De Vos, WM, Thas, O, De Weirdt, R, Kerckhof, FM, Van de Wiele, T (B43) 2013; 7
Jostins, L, Ripke, S, Weersma, RK, Duerr, RH, McGovern, DP, Hui, KY, Lee, JC, Schumm, LP, Sharma, Y, Anderson, CA, Essers, J, Mitrovic, M, Ning, K, Cleynen, I, Theatre, E, Spain, SL, Raychaudhuri, S, Goyette, P, Wei, Z, Abraham, C, Achkar, JP, Ahmad, T, Amininejad, L, Ananthakrishnan, AN, Andersen, V, Andrews, JM, Baidoo, L, Balschun, T, Bampton, PA, Bitton, A, Boucher, G, Brand, S, Buning, C, Cohain, A, Cichon, S, D’Amato, M, De Jong, D, Devaney, KL, Dubinsky, M, Edwards, C, Ellinghaus, D, Ferguson, LR, Franchimont, D, Fransen, K, Gearry, R, Georges, M, Gieger, C, Glas, J, Haritunians, T, Hart, A (B2) 2012; 491
Vince, AJ, McNeil, NI, Wager, JD, Wrong, OM (B45) 1990; 63
Winter, SE, Lopez, CA, Bäumler, AJ (B15) 2013; 14
Rutgeerts, P, Sandborn, WJ, Feagan, BG, Reinisch, W, Olson, A, Johanns, J, Travers, S, Rachmilewitz, D, Hanauer, SB, Lichtenstein, GR, de Villiers, WJ, Present, D, Sands, BE, Colombel, JF (B41) 2005; 353
van Dullemen, HM, van Deventer, SJ, Hommes, DW, Bijl, HA, Jansen, J, Tytgat, GN, Woody, J (B19) 1995; 109
Satsangi, J, Silverberg, MS, Vermeire, S, Colombel, JF (B48) 2006; 55
Papa, E, Docktor, M, Smillie, C, Weber, S, Preheim, SP, Gevers, D, Giannoukos, G, Ciulla, D, Tabbaa, D, Ingram, J, Schauer, DB, Ward, DV, Korzenik, JR, Xavier, RJ, Bousvaros, A, Alm, EJ (B7) 2012; 7
Chen, CC, Huang, JL, Chang, CJ, Kong, MS (B51) 2012; 55
Morgan, XC, Tickle, TL, Sokol, H, Gevers, D, Devaney, KL, Ward, DV, Reyes, JA, Shah, SA, LeLeiko, N, Snapper, SB, Bousvaros, A, Korzenik, J, Sands, BE, Xavier, RJ, Huttenhower, C (B11) 2012; 13
Fróes, RDSB, Pugas Carvalho, AT, Carneiro, AJDV, de Barros Moreira, AMH, Moreira, JPL, Luiz, RR, de Souza, HS (B36) 2017
Chen, L, Wang, W, Zhou, R, Ng, SC, Li, J, Huang, M, Zhou, F, Wang, X, Shen, B, A Kamm, M, Wu, K, Xia, B (B30) 2014; 93
Chu, H, Khosravi, A, Kusumawardhani, IP, Kwon, AH, Vasconcelos, AC, Cunha, LD, Mayer, AE, Shen, Y, Wu, WL, Kambal, A, Targan, SR, Xavier, RJ, Ernst, PB, Green, DR, McGovern, DP, Virgin, HW, Mazmanian, SK (B39) 2016; 352
Manichanh, C, Borruel, N, Casellas, F, Guarner, F (B3) 2012; 9
Zhou, YL, Xie, S, Wang, P, Zhang, T, Lin, MY, Tan, JS, Zhi, FC, Jiang, B, Chen, Y (B21) 2014; 15
Ott, SJ, Musfeldt, M, Wenderoth, DF, Hampe, J, Brant, O, Fölsch, UR, Timmis, KN, Schreiber, S (B32) 2004; 53
Chi, KR (B37) 2016; 540
Lennard-Jones, JE (B47) 1989; 170
Peng, X, Yu, KQ, Deng, GH, Jiang, YX, Wang, Y, Zhang, GX, Zhou, HW (B52) 2013; 95
Beaugerie, L, Seksik, P, Nion-Larmurier, I, Gendre, JP, Cosnes, J (B22) 2006; 130
Lozupone, C, Knight, R (B34) 2005; 71
Ogura, Y, Bonen, DK, Inohara, N, Nicolae, DL, Chen, FF, Ramos, R, Britton, H, Moran, T, Karaliuskas, R, Duerr, RH, Achkar, JP, Brant, SR, Bayless, TM, Kirschner, BS, Hanauer, SB, Nuñez, G, Cho, JH (B5) 2001; 411
Ng, SC, Tang, W, Ching, JY, Wong, M, Chow, CM, Hui, AJ, Wong, TC, Leung, VK, Tsang, SW, Yu, HH, Li, MF, Ng, KK, Kamm, MA, Studd, C, Bell, S, Leong, R, de Silva, HJ, Kasturiratne, A, Mufeena, MN, Ling, KL, Ooi, CJ, Tan, PS, Ong, D, Goh, KL, Hilmi, I, Pisespongsa, P, Manatsathit, S, Rerknimitr, R, Aniwan, S, Wang, YF, Ouyang, Q, Zeng, Z, Zhu, Z, Chen, MH, Hu, PJ, Wu, K, Wang, X, Simadibrata, M, Abdullah, M, Wu, JC, Sung, JJ, Chan, FK (B16) 2013; 145
Walters, WA, Xu, Z, Knight, R (B33) 2014; 588
Liu, JZ, van Sommeren, S, Huang, H, Ng, SC, Alberts, R, Takahashi, A, Ripke, S, Lee, JC, Jostins, L, Shah, T, Abedian, S, Cheon, JH, Cho, J, Dayani, NE, Franke, L, Fuyuno, Y, Hart, A, Juyal, RC, Juyal, G, Kim, WH, Morris, AP, Poustchi, H, Newman, WG, Midha, V, Orchard, TR, Vahedi, H, Sood, A, Sung, JY, Malekzadeh, R, Westra, HJ, Yamazaki, K, Yang, SK, Barrett, JC, Alizadeh, BZ, Parkes, M, Bk, T, Daly, MJ, Kubo, M, Anderson, CA, Weersma, RK (B38) 2015; 47
Lu, C, Waugh, A, Bailey, RJ, Cherry, R, Dieleman, LA, Gramlich, L, Matic, K, Millan, M, Kroeker, KI, Sadowski, D, Teshima, CW, Todoruk, D, Wong, C, Wong, K, Fedorak, RN (B50) 2012; 18
Andoh, A, Imaeda, H, Aomatsu, T, Inatomi, O, Bamba, S, Sasaki, M, Saito, Y, Tsujikawa, T, Fujiyama, Y (B12) 2011; 46
Van Assche, G, Dignass, A, Panes, J, Beaugerie, L, Karagiannis, J, Allez, M, Ochsenkühn, T, Orchard, T, Rogler, G, Louis, E, Kupcinskas, L, Mantzaris, G, Travis, S, Stange, E (B49) 2010; 4
Andoh, A, Kuzuoka, H, Tsujikawa, T, Nakamura, S, Hirai, F, Suzuki, Y, Matsui, T, Fujiyama, Y, Matsumoto, T (B13) 2012; 47
Sokol, H, Pigneur, B, Watterlot, L, Lakhdari, O, Bermúdez-Humarán, LG, Gratadoux, JJ, Blugeon, S, Bridonneau, C, Furet, JP, Corthier, G, Grangette, C, Vasquez, N, Pochart, P, Trugnan, G, Thomas, G, Blottière, HM, Doré, J, Marteau, P, Seksik, P, Langella, P (B46) 2008; 105
Fawcett, T (B58) 2006; 27
Frank, DN, Robertson, CE, Hamm, CM, Kpadeh, Z, Zhang, T, Chen, H, Zhu, W, Sartor, RB, Boedeker, EC, Harpaz, N, Pace, NR, Li, E (B10) 2011; 17
Costa, F, Mumolo, MG, Ceccarelli, L, Bellini, M, Romano, MR, Sterpi, C, Ricchiuti, A, Marchi, S, Bottai, M (B23) 2005; 54
References_xml – ident: e_1_3_2_3_2
  doi: 10.1038/nature11582
– ident: e_1_3_2_43_2
  doi: 10.1126/science.aaf3229
– ident: e_1_3_2_11_2
  doi: 10.1002/ibd.21339
– ident: e_1_3_2_26_2
  doi: 10.1159/000201441
– ident: e_1_3_2_13_2
  doi: 10.1007/s00535-010-0368-4
– ident: e_1_3_2_39_2
  doi: 10.1038/ng.3359
– ident: e_1_3_2_36_2
  doi: 10.1097/01.MIB.0000435759.05577.12
– ident: e_1_3_2_51_2
  doi: 10.3748/wjg.v18.i36.5058
– ident: e_1_3_2_10_2
  doi: 10.1016/j.chom.2014.02.005
– ident: e_1_3_2_15_2
  doi: 10.4103/0971-5916.162091
– ident: e_1_3_2_25_2
  doi: 10.1053/j.gastro.2010.11.058
– ident: e_1_3_2_16_2
  doi: 10.1038/embor.2013.27
– ident: e_1_3_2_22_2
  doi: 10.1111/1751-2980.12161
– ident: e_1_3_2_38_2
  doi: 10.1038/540S100a
– ident: e_1_3_2_2_2
  doi: 10.1136/gutjnl-2014-307410
– ident: e_1_3_2_14_2
  doi: 10.1007/s00535-012-0605-0
– ident: e_1_3_2_45_2
  doi: 10.1126/science.1198469
– ident: e_1_3_2_47_2
  doi: 10.1073/pnas.0804812105
– volume: 2
  start-page: 18
  year: 2002
  ident: e_1_3_2_60_2
  article-title: Classification and regression by randomForest
  publication-title: R News
– ident: e_1_3_2_37_2
  doi: 10.1007/s10198-017-0896-4
– ident: e_1_3_2_54_2
  doi: 10.1038/nmeth.f.303
– ident: e_1_3_2_57_2
  doi: 10.1186/gb-2011-12-6-r60
– ident: e_1_3_2_32_2
  doi: 10.1016/j.diagmicrobio.2012.11.022
– ident: e_1_3_2_28_2
  doi: 10.1038/ajg.2010.392
– ident: e_1_3_2_29_2
  doi: 10.1097/MIB.0000000000000036
– ident: e_1_3_2_7_2
  doi: 10.1136/gut.2005.073817
– ident: e_1_3_2_24_2
  doi: 10.1136/gut.2004.043406
– ident: e_1_3_2_52_2
  doi: 10.1097/MPG.0b013e318262a718
– ident: e_1_3_2_42_2
  doi: 10.1056/NEJMoa050516
– ident: e_1_3_2_48_2
  doi: 10.3109/00365528909091339
– ident: e_1_3_2_5_2
  doi: 10.1038/35079107
– ident: e_1_3_2_40_2
  doi: 10.1126/science.aad9948
– ident: e_1_3_2_34_2
  doi: 10.1016/j.febslet.2014.09.039
– ident: e_1_3_2_41_2
  doi: 10.1016/S0140-6736(02)08512-4
– ident: e_1_3_2_21_2
  doi: 10.1097/MEG.0000000000000447
– ident: e_1_3_2_33_2
  doi: 10.1136/gut.2003.025403
– ident: e_1_3_2_50_2
  doi: 10.1016/j.crohns.2009.12.003
– ident: e_1_3_2_12_2
  doi: 10.1186/gb-2012-13-9-r79
– ident: e_1_3_2_55_2
  doi: 10.1038/ismej.2011.139
– ident: e_1_3_2_44_2
  doi: 10.1038/ismej.2012.158
– ident: e_1_3_2_53_2
  doi: 10.1016/j.mimet.2013.07.015
– ident: e_1_3_2_56_2
  doi: 10.1038/nbt.2676
– ident: e_1_3_2_6_2
  doi: 10.1038/35079114
– ident: e_1_3_2_23_2
  doi: 10.1053/j.gastro.2005.12.019
– ident: e_1_3_2_49_2
  doi: 10.1136/gut.2005.082909
– ident: e_1_3_2_30_2
  doi: 10.1038/ajg.2015.149
– ident: e_1_3_2_46_2
  doi: 10.1079/BJN19900088
– ident: e_1_3_2_9_2
  doi: 10.1038/nrgastro.2014.45
– ident: e_1_3_2_19_2
  doi: 10.1053/j.gastro.2011.01.055
– ident: e_1_3_2_17_2
  doi: 10.1053/j.gastro.2013.04.007
– ident: e_1_3_2_4_2
  doi: 10.1038/nrgastro.2012.152
– ident: e_1_3_2_27_2
  doi: 10.1002/ibd.22861
– ident: e_1_3_2_18_2
  doi: 10.1038/nature11053
– ident: e_1_3_2_8_2
  doi: 10.1371/journal.pone.0039242
– ident: e_1_3_2_31_2
  doi: 10.1097/MD.0000000000000051
– ident: e_1_3_2_59_2
  doi: 10.1016/j.patrec.2005.10.010
– ident: e_1_3_2_35_2
  doi: 10.1128/AEM.71.12.8228-8235.2005
– ident: e_1_3_2_58_2
  doi: 10.18637/jss.v028.i05
– ident: e_1_3_2_20_2
  doi: 10.1016/0016-5085(95)90277-5
– volume: 64
  start-page: 1063
  year: 2015
  end-page: 1071
  ident: B1
  article-title: Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific
  publication-title: Gut
  doi: 10.1136/gutjnl-2014-307410
– volume: 411
  start-page: 603
  year: 2001
  end-page: 606
  ident: B5
  article-title: A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease
  publication-title: Nature
  doi: 10.1038/35079114
– volume: 486
  start-page: 222
  year: 2012
  end-page: 227
  ident: B17
  article-title: Human gut microbiome viewed across age and geography
  publication-title: Nature
  doi: 10.1038/nature11053
– volume: 110
  start-page: 921
  year: 2015
  end-page: 930
  ident: B29
  article-title: Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2015.149
– volume: 47
  start-page: 979
  year: 2015
  end-page: 986
  ident: B38
  article-title: Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
  publication-title: Nat Genet
– volume: 353
  start-page: 2462
  year: 2005
  end-page: 2476
  ident: B41
  article-title: Infliximab for induction and maintenance therapy for ulcerative colitis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa050516
– volume: 46
  start-page: 479
  year: 2011
  end-page: 486
  ident: B12
  article-title: Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-010-0368-4
– volume: 352
  start-page: 1116
  year: 2016
  end-page: 1120
  ident: B39
  article-title: Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease
  publication-title: Science
  doi: 10.1126/science.aad9948
– volume: 7
  start-page: 949
  year: 2013
  end-page: 961
  ident: B43
  article-title: Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model
  publication-title: ISME J
  doi: 10.1038/ismej.2012.158
– volume: 27
  start-page: 861
  year: 2006
  end-page: 874
  ident: B58
  article-title: An introduction to ROC analysis
  publication-title: Pattern Recognit Lett
  doi: 10.1016/j.patrec.2005.10.010
– volume: 359
  start-page: 1541
  year: 2002
  end-page: 1549
  ident: B40
  article-title: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)08512-4
– volume: 7
  start-page: 335
  year: 2010
  end-page: 336
  ident: B53
  article-title: QIIME allows analysis of high-throughput community sequencing data
  publication-title: Nat Methods
  doi: 10.1038/nmeth.f.303
– volume: 95
  start-page: 455
  year: 2013
  end-page: 462
  ident: B52
  article-title: Comparison of direct boiling method with commercial kits for extracting fecal microbiome DNA by Illumina sequencing of 16S rRNA tags
  publication-title: J Microbiol Methods
  doi: 10.1016/j.mimet.2013.07.015
– volume: 55
  start-page: 541
  year: 2012
  end-page: 547
  ident: B51
  article-title: Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children
  publication-title: J Pediatr Gastroenterol Nutr
  doi: 10.1097/MPG.0b013e318262a718
– volume: 53
  start-page: 685
  year: 2004
  end-page: 693
  ident: B32
  article-title: Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease
  publication-title: Gut
  doi: 10.1136/gut.2003.025403
– volume: 13
  start-page: R79
  year: 2012
  ident: B11
  article-title: Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
  publication-title: Genome Biol
  doi: 10.1186/gb-2012-13-9-r79
– volume: 352
  start-page: 608
  year: 2016
  end-page: 612
  ident: B42
  article-title: Helminth infection promotes colonization resistance via type 2 immunity
  publication-title: Science
  doi: 10.1126/science.aaf3229
– volume: 55
  start-page: 749
  year: 2006
  end-page: 753
  ident: B48
  article-title: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
  publication-title: Gut
  doi: 10.1136/gut.2005.082909
– volume: 6
  start-page: 610
  year: 2012
  end-page: 618
  ident: B54
  article-title: An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea
  publication-title: ISME J
  doi: 10.1038/ismej.2011.139
– volume: 31
  start-page: 814
  year: 2013
  end-page: 821
  ident: B55
  article-title: Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.2676
– volume: 27
  start-page: 1270
  year: 2015
  end-page: 1275
  ident: B20
  article-title: Infliximab for the treatment of Crohn’s disease
  publication-title: Eur J Gastroenterol Hepatol
  doi: 10.1097/MEG.0000000000000447
– year: 2017
  ident: B36
  article-title: The socio-economic impact of work disability due to inflammatory bowel disease in Brazil
  publication-title: Eur J Health Econ
  doi: 10.1007/s10198-017-0896-4
– volume: 2
  start-page: 18
  year: 2002
  end-page: 22
  ident: B59
  article-title: Classification and regression by randomForest
  publication-title: R News
– volume: 15
  start-page: 382
  year: 2014
  end-page: 392
  ident: B9
  article-title: The treatment-naive microbiome in new-onset Crohn’s disease
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2014.02.005
– volume: 140
  start-page: 1817
  year: 2011
  end-page: 1826.e2
  ident: B24
  article-title: The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2010.11.058
– volume: 18
  start-page: 5058
  year: 2012
  end-page: 5064
  ident: B50
  article-title: Crohn’s disease genotypes of patients in remission vs relapses after infliximab discontinuation
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v18.i36.5058
– volume: 75
  start-page: 245
  year: 2013
  end-page: 251
  ident: B31
  article-title: The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2012.11.022
– volume: 58
  start-page: 176
  year: 1997
  end-page: 180
  ident: B25
  article-title: Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein
  publication-title: Digestion
  doi: 10.1159/000201441
– volume: 71
  start-page: 8228
  year: 2005
  end-page: 8235
  ident: B34
  article-title: UniFrac: a new phylogenetic method for comparing microbial communities
  publication-title: Appl Environ Microbiol
  doi: 10.1128/AEM.71.12.8228-8235.2005
– volume: 11
  start-page: 268
  year: 2014
  ident: B8
  article-title: IBD. Understanding gut microbiota in new-onset Crohn’s disease
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/nrgastro.2014.45
– volume: 170
  start-page: 2 16
  year: 1989
  end-page: 6 19
  ident: B47
  article-title: Classification of inflammatory bowel disease
  publication-title: Scand J Gastroenterol Suppl ;discussion
  doi: 10.3109/00365528909091339
– volume: 106
  start-page: 199
  year: 2011
  end-page: 212
  ident: B27
  article-title: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
  publication-title: Am J Gastroenterol ;quiz 213
– volume: 130
  start-page: 650
  year: 2006
  end-page: 656
  ident: B22
  article-title: Predictors of Crohn’s disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2005.12.019
– volume: 14
  start-page: 319
  year: 2013
  end-page: 327
  ident: B15
  article-title: The dynamics of gut-associated microbial communities during inflammation
  publication-title: EMBO Rep
  doi: 10.1038/embor.2013.27
– volume: 109
  start-page: 129
  year: 1995
  end-page: 135
  ident: B19
  article-title: Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
  publication-title: Gastroenterology
  doi: 10.1016/0016-5085(95)90277-5
– volume: 20
  start-page: 978
  year: 2014
  end-page: 986
  ident: B28
  article-title: Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn’s disease
  publication-title: Inflamm Bowel Dis
  doi: 10.1097/MIB.0000000000000036
– volume: 63
  start-page: 17
  year: 1990
  end-page: 26
  ident: B45
  article-title: The effect of lactulose, pectin, arabinogalactan and cellulose on the production of organic acids and metabolism of ammonia by intestinal bacteria in a faecal incubation system
  publication-title: Br J Nutr
  doi: 10.1079/BJN19900088
– volume: 9
  start-page: 599
  year: 2012
  end-page: 608
  ident: B3
  article-title: The gut microbiota in IBD
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/nrgastro.2012.152
– volume: 140
  start-page: 1785
  year: 2011
  end-page: 1794
  ident: B18
  article-title: Epidemiology and natural history of inflammatory bowel diseases
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2011.01.055
– volume: 540
  start-page: S100
  year: 2016
  end-page: SS102
  ident: B37
  article-title: Epidemiology: rising in the east
  publication-title: Nature
  doi: 10.1038/540S100a
– volume: 331
  start-page: 337
  year: 2011
  end-page: 341
  ident: B44
  article-title: Induction of colonic regulatory T cells by indigenous Clostridium species
  publication-title: Science
  doi: 10.1126/science.1198469
– volume: 17
  start-page: 179
  year: 2011
  end-page: 184
  ident: B10
  article-title: Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.21339
– volume: 588
  start-page: 4223
  year: 2014
  end-page: 4233
  ident: B33
  article-title: Meta-analyses of human gut microbes associated with obesity and IBD
  publication-title: FEBS Lett
  doi: 10.1016/j.febslet.2014.09.039
– volume: 93
  start-page: e51
  year: 2014
  ident: B30
  article-title: Characteristics of fecal and mucosa-associated microbiota in Chinese patients with inflammatory bowel disease
  publication-title: Medicine
  doi: 10.1097/MD.0000000000000051
– volume: 7
  year: 2012
  ident: B7
  article-title: Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0039242
– volume: 12
  start-page: R60
  year: 2011
  ident: B56
  article-title: Metagenomic biomarker discovery and explanation
  publication-title: Genome Biol
  doi: 10.1186/gb-2011-12-6-r60
– volume: 28
  year: 2008
  ident: B57
  article-title: Building predictive models in R using the Caret package
  publication-title: J Stat Softw
  doi: 10.18637/jss.v028.i05
– volume: 47
  start-page: 1298
  year: 2012
  end-page: 1307
  ident: B13
  article-title: Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-012-0605-0
– volume: 19
  start-page: 2906
  year: 2013
  end-page: 2918
  ident: B35
  article-title: Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease
  publication-title: Inflamm Bowel Dis
  doi: 10.1097/01.MIB.0000435759.05577.12
– volume: 411
  start-page: 599
  year: 2001
  end-page: 603
  ident: B4
  article-title: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease
  publication-title: Nature
  doi: 10.1038/35079107
– volume: 54
  start-page: 364
  year: 2005
  end-page: 368
  ident: B23
  article-title: Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease
  publication-title: Gut
  doi: 10.1136/gut.2004.043406
– volume: 145
  start-page: 158
  year: 2013
  end-page: 165.e2
  ident: B16
  article-title: Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn’s and Colitis Epidemiology Study
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2013.04.007
– volume: 491
  start-page: 119
  year: 2012
  end-page: 124
  ident: B2
  article-title: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
  publication-title: Nature
  doi: 10.1038/nature11582
– volume: 55
  start-page: 205
  year: 2006
  end-page: 211
  ident: B6
  article-title: Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach
  publication-title: Gut
  doi: 10.1136/gut.2005.073817
– volume: 142
  start-page: 23
  year: 2015
  end-page: 32
  ident: B14
  article-title: Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid
  publication-title: Indian J Med Res
  doi: 10.4103/0971-5916.162091
– volume: 18
  start-page: 1894
  year: 2012
  end-page: 1899
  ident: B26
  article-title: Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.22861
– volume: 15
  start-page: 483
  year: 2014
  end-page: 490
  ident: B21
  article-title: Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China
  publication-title: J Dig Dis
  doi: 10.1111/1751-2980.12161
– volume: 105
  start-page: 16731
  year: 2008
  end-page: 16736
  ident: B46
  article-title: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0804812105
– volume: 4
  start-page: 7
  year: 2010
  end-page: 27
  ident: B49
  article-title: The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis
  publication-title: J Crohns Colitis
  doi: 10.1016/j.crohns.2009.12.003
SSID ssj0001637129
Score 2.5008361
Snippet In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel...
Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and...
ABSTRACTGut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across...
ABSTRACT Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across...
SourceID doaj
pubmedcentral
proquest
asm2
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
SubjectTerms Biomarkers
Crohn's disease
Diagnosis
Disease
disease activity
Dysbacteriosis
Fecal microflora
Feces
Firmicutes
Gastroenterology
Geography
gut microbiota
Health care
Hospitals
Host-Microbe Biology
Immunotherapy
Inflammatory bowel disease
Inflammatory bowel diseases
Infliximab
infliximab treatment
Intestinal microflora
Intestine
Laboratories
Microbiomes
Microbiota
Minority & ethnic groups
Monoclonal antibodies
Multiculturalism & pluralism
Noninvasive evaluation
Pathogenesis
Research Article
Studies
TNF inhibitors
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Ulcerative colitis
SummonAdditionalLinks – databaseName: American Society for Microbiology Open Access
  dbid: AAUOK
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1baxUxEA61RfBFvHdtlQiCIKxubpvk8VRbq1Ir4oG-LcluQhe6e6RnD9Y_0N_dSfZSj5Ti00I2w04yM8lsvskMQq-dVrYylU-14DTlDtTYMKNTazPDKLOGZ-G-89G3_HDOv5yIkw2Uj3dhhhlcvjPLJgL5k2VT9b7psxsvA3wAAibyDtoSVHMwyK3ZbH789fp0JWcSdrIBxryRFtZg-AZd249i2v6bfM1_Qyb_2oMOHqD7g_OIZ720H6IN1z5Cd_tykn8eo8tPqw4f1X1qpc7g41D7ZImH2AsghJ5NCMeBRhPZwfvdaVuX4InjusWfWw_60UTcHe8tfrsz_LHHb-AZI_JqIGyr2LG-qBtj8Y8-xtbh7-cB8glifoLmB_s_PxymQ52F1AitutSRUhNY5ry31FmZc-0MUT4vJWPSVxqcAqc9oR7cERLOeKk0lWXMZbyUvBLsKdpsF63bRphWkpRcGKsZ4dR6w0mpPPGauqwspUvQmzDpxSjmIv6DUFWM4imieAoiE5SNcinKIV15qJpxdhvJ24nkV5-r47bOe0HYU8eQZjs2gNIVg9UWAfVlUjvPneQBAM0YF06A1sN8VYQkaHdUleshxTxWWhEuEvRqeg1WG6AY07rFCoatwbPludLAx7NesyZOQKEzDktpguSazq2xuv6mrU9jZnAhdaYkff7fs7yD7oEHqPozpV202Z2v3Avwsjr7cjCpKzzeKy0
  priority: 102
  providerName: American Society for Microbiology
– databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9UwFA9yQfBFdH5VtxFBEISy5qNN8-jc5hSmIg72VpLmhBXWXtntRf0H_Ls9SXqv94rMF58KaUJPcn5pTnJOfoeQF6Br64zzuS4lzyUgjI0wOre2MIILa2QR7juffahOz-X7i_JiI9VXiAlL9MBp4A6C400oDV6CksEHVQhZQokfZs65dKsX17yNzVQ8XamEwpVscmPiP_igT8zIi-B6QHCEBGUzs-j51noUafv_Zmv-GTK5sQad3CN3J-ORvk5C3ye3YNght1M6yR8PyM-3y5GedYlaaTT0Y8h9sqBT7AU2xJp9CMfBQhPFocfj5dC1aInTbqDvBo_46KPfnR7Ov8EVPUr-G3zGiLwOGw4uVuy-d72x9HOKsQX66Tq4fIKaH5Lzk-Mvb07zKc9CbkpdjzmwVuNggveWg1WV1GBY7atWCaG802gUgPaMezRHWDjj5co4KwQUslXSleIRmQ3zAZ4Qyp1irSyN1YJJbr2RrK0985pD0bYKMvIyDHozTZRFE_cgvG5W6mmiehqmMlKs9NK0E115yJpxdVOTV-smXxNXx02VD4Oy1xUDzXYsQPA1E_iaf4EvI7srqPzuUuSx0jWTZUaer1_jrA2uGDPAfInd1mjZyqrWKMfjhKy1JFzLQuKvNCNqC3Nbom6_GbrLyAxeKl3Uij_9H317Ru6gcVin46ZdMhuvl7CHBtho9-Nc-wWzbTL0
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fi9QwEA7nieiL6Klnz1MiCIJQbX50kzyIeHrnKayKuHBvJWkTt7DtertdvP0H_LudpNnVlWWfCm2mTDszydfM9BuEnlklTaUrl6qc05RbcGPNtEqNyTSjzGie-f-dh58H5yP-6SK_2EOr9lbxBc63ftr5flKj2eTl1eXyDQT86_4HGPmqieTePqsAdifiGroOC5PwDQ2GEe2HLZcBE7C8xdzmVkmYmPW8oRuLVODy3wZA_6-j_GdhOruDbkdEid_2LnAX7dn2AN3oe0wuD9DN2OZ8vLyHfn9YdHhY99xLncZffHOUOY7FGXATkGp8vQ6c1EE1fNqN27oEqI7rFn9sHThQExLz-GT6y07w-z7BA8dQsleDYFuFgfVV3WiDv_VFuBZ_nfmckPeD-2h0dvr93XkaGzGkOleySy0pFYF50DlDrREDrqwm0g1KwZhwlQLUYJUj1AFeIX4TmApdGcZsxkvBq5w9QPvttLUPEaaVICXPtVGMcGqc5qSUjjhFbVaWwibouTdAsXKEInykUFk0PbP1vAimKohIULayUVFGPnPfVmOyS-TFWuRnT-axa_CJN_x6oOfhDiemsx9FDOvCp4WZUNZxK7jPkGaM5zaHsID3VRGSoOOV2_x9pEB0pSTheYKeri9DWPtcjW7tdAGPrQD68oFUoMdh72VrTajiGYe5NkFiw_82VN280tbjQB2eC5VJQY92q_UI3QJcKPudpmO0380W9jFgr848CRH1B5BZMyY
  priority: 102
  providerName: Scholars Portal
Title Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction
URI https://www.ncbi.nlm.nih.gov/pubmed/29404425
https://journals.asm.org/doi/10.1128/msystems.00188-17
https://www.proquest.com/docview/2009298145
https://www.proquest.com/docview/1995146897
https://pubmed.ncbi.nlm.nih.gov/PMC5790872
https://doaj.org/article/6452379ef4e7497990345e5cca1ddd11
Volume 3
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELegE4IXBANGYVRGQkJCihZ_pI6fUAsdA9RtmqjUt8hObBppSUebCvYP8HdzdtyWItSXRIrt6JL78OXu8juE3hiZ6kIVNpIJpxE3IMaKKRlpHStGmVY8dv87j8_7ZxP-ZZpMQ8BtGcoq1zbRG-pinrsY-YlHB5Ip4cn7mx-R6xrlsquhhcZddOCgy5xUi6nYxlj6TMB-FpKZYIlPqoAD7hIQICKuTVlHLSu6syt58P7_eZz_Fk7-tROdPkIPgwuJBy3PH6M7pj5E99qmkreH6H7oaz67fYJ-f1o1eFy2YEuNwheuG8oSh2oMuAmsqlyBDlxUnjQ8amZ1mYNvjssaf64tSEzlM_F4OP9prvHHNqMDZ1-jV8LCuvATy19lpTS-aqtuDb5cuCSQY_xTNDkdfftwFoXOC5FKZNpEhuSSgOGzVlOjRZ9Lo0hq-7lgTNhCgptgpCXUgoNCXNSXClVoxkzMc8GLhD1DnXpem-cI00KQnCdKS0Y41VZxkqeWWElNnOfCdNFbx4AsqM4y818lNM2qFsp6mXlWZUR0UbzmUZYHAHPXR-N635J3myU3LXrHvslDx_jNRAe87S_MF9-zoMeZywMzIY3lRnCXEo0ZT0wCegDvqyCki47XYrN9pK3sdtHrzTDosUvOqNrMV_DYEnxd3k8l0HHUStmGEip5zMG4dpHYkb8dUndH6nLmscITIeNU0Bf7yXqJHoAjmLahpWPUaRYr8wqcrUb3vEb10MFgMLn4Cufh6PzyqudDF3Ac8_QPEFAznQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamIjReEIxbYICRQEhI0eJL6vgBIcY2WrYOhDapb8FObBppSUebavQP8HP4jRw7aUsR6tueIiV2dJxztc_J-RB6aWSic5XbUMachtyAGCumZKh1pBhlWvHI_e88OO32zvmnYTzcQr8X_8K4ssqFTfSGOh9n7ox8z3cHkgnh8bvLH6FDjXLZ1QWERiMWx2Z-BVu26dv-AfD3FaVHh2cfemGLKhCqWCZ1aEgmCSi1tZoaLbpcGkUS280EY8LmElygkZZQC86XuBNNKlSuGTMRzwTPHUoEmPwb4Hgjt9kTQ7E60-kyAf6zTZ6C5d8r277jLuEBIulg0TpqWtI1L-jBAv4X4f5bqPmX5zu6g263ISt-38jYXbRlqh10swGxnO-g7RZHfTS_h359nNV4UDTNnWqFPzv0lSluqz_gJTCrdAVBcFN50vBhPaqKDPYCuKhwv7IgoaXP_OP98ZW5wAdNBgmuviawgIlV7gcWP4tSafy1qfI1-MvEJZ2coN1H59fCkweoU40r8whhmguS8VhpyQin2ipOssQSK6mJskyYAL12DEhbVZ2mfhdEk7RsWmdPU8-qlIgARQsepVnbMN3hdlxsmvJmOeWy6RayafC-Y_xyoGv07W-MJ9_T1m6kLu_MhDSWG8FdCjZiPDYx6B18r5yQAO0uxGa1pJWuBOjF8jHYDZcMUpUZz2DZEmJr3k0k0PGwkbIlJVTyiIMxD5BYk781UtefVMXI9yaPhYwSQR9vJus52u6dDU7Sk_7p8RN0C4LQpDnW2kWdejIzTyHQq_Uzr10Yfbtudf4DlM1sjw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamTlxeJhi3jgFGAiEhRY0dp44fEKK0ZWWsVBOT9pbZiU0jLeloU43-AX4Uv45jJ20pQn3bU6TEjo5zrvY5OR9Cr7SIVCpT44mQUY9pEGMZSOEp5cuABkoy3_7vfDJsH52xz-fh-Q76vfwXxpZVLm2iM9TpJLFn5C3XHUhEhIUtU5dFjLr991c_PIsgZTOtSziNSkSO9eIatm-zd4Mu8Po1pf3et49HXo0w4MlQRKWnSSIIKLgximrF20xoSSLTTngQcJMKcIdaGEINOGJiTzcpl6kKAu2zhLPUIkaA-d_ldlfUQLud3nB0uj7haQccvGmdSgU_0MrrLuQ2_QECakHSGnKW0w2f6KAD_hfv_lu2-Zcf7N9De3UAiz9UEncf7ehiH92qIC0X--hOjao-XjxAvz7NS3ySVa2eSom_WiyWGa5rQeAlMCu35UFwUzrScK8cF1kCOwOcFXhQGJDX3NUB4M7kWl_ibpVPgqurEMxgYpG6gdnPLJcKn1Y1vxqPpjYFZcXuITq7Ea48Qo1iUugnCNOUk4SFUomAMKqMZCSJDDGCaj9JuG6iN5YBca24s9jtiWgU51Uj7VnsWBUT3kT-kkdxUrdPtygel9umvF1Nuap6h2wb3LGMXw20bb_djcn0e1xbkdhmoQMutGGaM5uQ9QMW6hC0EL5XSkgTHS7FZr2kteY00cvVY7AiNjUkCz2Zw7IFRNqsHQmg43ElZStKqGA-A9PeRHxD_jZI3XxSZGPXqTzkwo84PdhO1gt0G1Q5_jIYHj9FdyEijaozrkPUKKdz_QyivlI9r9ULo4ub1ug_bMxyKg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gut+Microbiota+Offers+Universal+Biomarkers+across+Ethnicity+in+Inflammatory+Bowel+Disease+Diagnosis+and+Infliximab+Response+Prediction&rft.jtitle=mSystems&rft.au=Zhou+Youlian&rft.au=Xu+Zhenjiang+Zech&rft.au=He%2C+Yan&rft.au=Yang%2C+Yunsheng&rft.date=2018-01-01&rft.pub=American+Society+for+Microbiology&rft.eissn=2379-5077&rft.volume=3&rft.issue=1&rft_id=info:doi/10.1128%2FmSystems.00188-17&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2379-5077&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2379-5077&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2379-5077&client=summon